JP2012510461A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012510461A5 JP2012510461A5 JP2011538092A JP2011538092A JP2012510461A5 JP 2012510461 A5 JP2012510461 A5 JP 2012510461A5 JP 2011538092 A JP2011538092 A JP 2011538092A JP 2011538092 A JP2011538092 A JP 2011538092A JP 2012510461 A5 JP2012510461 A5 JP 2012510461A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- antibody
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08291116.5 | 2008-11-28 | ||
| EP08291116A EP2191840A1 (en) | 2008-11-28 | 2008-11-28 | Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan |
| PCT/IB2009/055389 WO2010061357A1 (en) | 2008-11-28 | 2009-11-27 | Antitumor combinations containing antibodies recognizing specifically cd38 and melphalan |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015107404A Division JP6148696B2 (ja) | 2008-11-28 | 2015-05-27 | Ｃｄ３８を特異的に認識する抗体およびメルファランを含有する抗腫瘍性組合せ剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012510461A JP2012510461A (ja) | 2012-05-10 |
| JP2012510461A5 true JP2012510461A5 (https=) | 2012-11-22 |
Family
ID=40578382
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011538092A Withdrawn JP2012510461A (ja) | 2008-11-28 | 2009-11-27 | Ｃｄ３８を特異的に認識する抗体およびメルファランを含有する抗腫瘍性組合せ剤 |
| JP2015107404A Active JP6148696B2 (ja) | 2008-11-28 | 2015-05-27 | Ｃｄ３８を特異的に認識する抗体およびメルファランを含有する抗腫瘍性組合せ剤 |
| JP2017037860A Pending JP2017141233A (ja) | 2008-11-28 | 2017-03-01 | Ｃｄ３８を特異的に認識する抗体およびメルファランを含有する抗腫瘍性組合せ剤 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015107404A Active JP6148696B2 (ja) | 2008-11-28 | 2015-05-27 | Ｃｄ３８を特異的に認識する抗体およびメルファランを含有する抗腫瘍性組合せ剤 |
| JP2017037860A Pending JP2017141233A (ja) | 2008-11-28 | 2017-03-01 | Ｃｄ３８を特異的に認識する抗体およびメルファランを含有する抗腫瘍性組合せ剤 |
Country Status (33)
| Country | Link |
|---|---|
| US (1) | US9259406B2 (https=) |
| EP (2) | EP2191840A1 (https=) |
| JP (3) | JP2012510461A (https=) |
| KR (1) | KR101733252B1 (https=) |
| CN (1) | CN102264385B (https=) |
| AR (1) | AR074219A1 (https=) |
| AU (1) | AU2009321249B2 (https=) |
| BR (1) | BRPI0921864B1 (https=) |
| CA (1) | CA2744990C (https=) |
| CL (1) | CL2011001254A1 (https=) |
| CO (1) | CO6440557A2 (https=) |
| CR (1) | CR20110280A (https=) |
| EA (1) | EA026867B1 (https=) |
| EC (1) | ECSP11011062A (https=) |
| HN (1) | HN2011001417A (https=) |
| IL (1) | IL213116B (https=) |
| MA (1) | MA32896B1 (https=) |
| ME (1) | ME01136B (https=) |
| MX (1) | MX342625B (https=) |
| MY (1) | MY164577A (https=) |
| NI (1) | NI201100105A (https=) |
| NZ (1) | NZ593027A (https=) |
| PA (1) | PA8850101A1 (https=) |
| PE (1) | PE20120340A1 (https=) |
| PY (1) | PY09043215A (https=) |
| SG (1) | SG171820A1 (https=) |
| SV (1) | SV2011003924A (https=) |
| TN (1) | TN2011000232A1 (https=) |
| TW (1) | TWI454260B (https=) |
| UA (1) | UA107069C2 (https=) |
| UY (1) | UY32263A (https=) |
| WO (1) | WO2010061357A1 (https=) |
| ZA (1) | ZA201103925B (https=) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0816777B2 (ja) | 1988-10-13 | 1996-02-21 | 富士写真フイルム株式会社 | 画像形成方法 |
| EP2191840A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan |
| CA2796464C (en) * | 2010-04-16 | 2021-08-03 | Immune Disease Institute, Inc. | Sustained polypeptide expression from synthetic, modified rnas and uses thereof |
| WO2012019168A2 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| SI2621531T1 (sl) | 2010-09-27 | 2017-06-30 | Morphosys Ag | Anti-cd38 protitelo in lenalidomid ali bortezomib za zdravljenje multiplega mieloma in nhl |
| RU2013120302A (ru) | 2010-10-01 | 2014-11-20 | Модерна Терапьютикс, Инк. | Сконструированные нуклеиновые кислоты и способы их применения |
| UA112170C2 (uk) * | 2010-12-10 | 2016-08-10 | Санофі | Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб |
| JOP20210044A1 (ar) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| EP2691101A2 (en) | 2011-03-31 | 2014-02-05 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| RU2648950C2 (ru) | 2011-10-03 | 2018-04-02 | Модерна Терапьютикс, Инк. | Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение |
| CN104114572A (zh) | 2011-12-16 | 2014-10-22 | 现代治疗公司 | 经修饰的核苷、核苷酸和核酸组合物 |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| AU2013243948A1 (en) | 2012-04-02 | 2014-10-30 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins associated with human disease |
| US9254311B2 (en) | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| JP6426093B2 (ja) | 2012-09-25 | 2018-11-28 | モルフォシス・アーゲー | 組み合わせ及びその使用 |
| WO2014081507A1 (en) | 2012-11-26 | 2014-05-30 | Moderna Therapeutics, Inc. | Terminally modified rna |
| US10342869B2 (en) | 2012-12-07 | 2019-07-09 | The Regents Of The University Of California | Compositions comprising anti-CD38 antibodies and lenalidomide |
| UA118255C2 (uk) * | 2012-12-07 | 2018-12-26 | Санофі | Композиція, яка містить антитіло до cd38 і леналідомід |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
| JP2016538829A (ja) | 2013-10-03 | 2016-12-15 | モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | 低密度リポタンパク質受容体をコードするポリヌクレオチド |
| SG10201803288RA (en) | 2013-10-31 | 2018-05-30 | Sanofi Sa | Specific anti-cd38 antibodies for treating human cancers |
| US9732154B2 (en) | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
| US9603927B2 (en) | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
| US10617757B2 (en) | 2014-08-08 | 2020-04-14 | The Regents Of The University Of California | Methods for treating multiple myeloma |
| MX386886B (es) | 2014-09-09 | 2025-03-12 | Janssen Biotech Inc | Combinación de anticuerpos anti-cd38 y ácido todo-trans retinoico para usarse en terapias. |
| AU2015358615B2 (en) | 2014-12-04 | 2021-08-05 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute myeloid leukemia |
| MX389805B (es) | 2015-05-20 | 2025-03-11 | Janssen Biotech Inc | Anticuerpos anti-cd38 para el tratamiento de amiloidosis de cadena ligera y otras enfermedades malignas hematológicas positivas para cd38. |
| AU2016282674B2 (en) | 2015-06-22 | 2022-01-13 | Janssen Biotech, Inc. | Combination therapies for heme malignancies with anti-CD38 antibodies and survivin inhibitors |
| US20170044265A1 (en) | 2015-06-24 | 2017-02-16 | Janssen Biotech, Inc. | Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38 |
| DK3827845T3 (da) | 2015-11-03 | 2022-05-23 | Janssen Biotech Inc | Subkutane formuleringer af anti-cd38-antistoffer og anvendelser deraf |
| US10781261B2 (en) | 2015-11-03 | 2020-09-22 | Janssen Biotech, Inc. | Subcutaneous formulations of anti-CD38 antibodies and their uses |
| JP2019527678A (ja) | 2016-06-28 | 2019-10-03 | ユーエムセー・ユトレヒト・ホールディング・ベー・フェー | ＣＤ３８に特異的に結合する抗体によるＩｇＥ媒介疾患の治療 |
| MA45674A (fr) | 2016-07-15 | 2019-05-22 | Takeda Pharmaceuticals Co | Méthodes et matériaux permettant d'évaluer une réponse à des traitements de déplétion de plasmoblastes et de plasmocytes |
| WO2019035938A1 (en) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF |
| JP2021502961A (ja) | 2017-10-31 | 2021-02-04 | ヤンセン バイオテツク，インコーポレーテツド | 高リスク多発性骨髄腫の治療方法 |
| US20210145778A1 (en) * | 2018-01-01 | 2021-05-20 | Orbicular Pharmaceutical Technologies Pvt. Ltd. | Stable Liquid Compositions of Melphalan |
| KR20210006321A (ko) | 2018-01-12 | 2021-01-18 | 다케다 야쿠힌 고교 가부시키가이샤 | 항-cd38 항체의 피하 투여 |
| US12274733B2 (en) | 2018-09-28 | 2025-04-15 | President And Fellows Of Harvard College | Cellular reprogramming to reverse aging and promote organ and tissue regeneration |
| MX2021003663A (es) | 2018-09-28 | 2021-05-28 | Harvard College | Reprogramacion celular para revertir el envejecimiento y promover la regeneracion de organos y tejidos. |
| EP3938394A1 (en) | 2019-03-15 | 2022-01-19 | MorphoSys AG | Anti-cd38 antibodies and pharmaceutical compositions thereof for the treatment of autoantibody-mediated autoimmune disease |
| US11655302B2 (en) | 2019-06-10 | 2023-05-23 | Sanofi | Anti-CD38 antibodies and formulations |
| MX2022006882A (es) | 2019-12-05 | 2022-11-08 | Sanofi Aventis Us Llc | Formulaciones de anticuerpos anti-cd38 para administracion subcutanea. |
| WO2022152823A1 (en) | 2021-01-14 | 2022-07-21 | Morphosys Ag | Anti-cd38 antibodies and their uses |
| TW202302642A (zh) | 2021-03-01 | 2023-01-16 | 德商莫菲西斯公司 | 用於治療抗體介導移植物排斥用途之抗ｃｄ３８抗體 |
| TW202321303A (zh) | 2021-07-19 | 2023-06-01 | 德商莫菲西斯公司 | 抗pla2r自體抗體媒介膜性腎病變之治療 |
| US12252518B2 (en) | 2023-01-06 | 2025-03-18 | Life Biosciences, Inc. | Methods of treating non-arteritic anterior ischemic optic neuropathy |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB750155A (en) | 1953-03-17 | 1956-06-13 | Nat Res Dev | Substituted alanines |
| US3032585A (en) | 1954-12-03 | 1962-05-01 | Nat Res Dev | Process for the production of p-bis-(2-chloroethyl)-aminophenylalanine |
| US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
| US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| EP1690934A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| CA2219361C (en) | 1995-04-27 | 2012-02-28 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| EP1500329B1 (en) | 1996-12-03 | 2012-03-21 | Amgen Fremont Inc. | Human antibodies that specifically bind human TNF alpha |
| BRPI9809391B8 (pt) | 1997-04-14 | 2021-05-25 | Amgen Res Munich Gmbh | processo para a produção de um receptor de antígeno anti-humano, anticorpo humano e composição farmacêutica |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| WO1999062526A2 (en) * | 1998-06-05 | 1999-12-09 | Mayo Foundation For Medical Education And Research | Use of genetically engineered antibodies to cd38 to treat multiple myeloma |
| US7223397B1 (en) | 1999-01-07 | 2007-05-29 | Research Development Foundation | Potentiation of anti-CD38-Immunotoxin cytotoxicity |
| GB0221574D0 (en) | 2002-09-17 | 2002-10-23 | Isis Innovation | Treatments |
| DK2511297T3 (en) | 2004-02-06 | 2015-06-15 | Morphosys Ag | Human anti-CD38 antibodies and their applications |
| EP2567976B1 (en) * | 2005-03-23 | 2017-07-19 | Genmab A/S | Antibodies against CD38 for treatment of multiple myeloma |
| EP3569245A1 (en) | 2006-09-26 | 2019-11-20 | Genmab A/S | Combination treatment of cd38-expressing tumors |
| US20080092384A1 (en) * | 2006-10-16 | 2008-04-24 | Schaake Mark D | Installation of Middle Bearing for a Crankshaft |
| EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| EP2191840A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan |
| EP2191841A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine |
| EP2191843A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide |
-
2008
- 2008-11-28 EP EP08291116A patent/EP2191840A1/en not_active Ceased
-
2009
- 2009-11-25 PY PY200909043215A patent/PY09043215A/es unknown
- 2009-11-25 PA PA20098850101A patent/PA8850101A1/es unknown
- 2009-11-25 UY UY0001032263A patent/UY32263A/es not_active Application Discontinuation
- 2009-11-25 TW TW098140158A patent/TWI454260B/zh active
- 2009-11-25 AR ARP090104545A patent/AR074219A1/es not_active Application Discontinuation
- 2009-11-27 CN CN200980148094.4A patent/CN102264385B/zh active Active
- 2009-11-27 ME MEP-2011-93A patent/ME01136B/me unknown
- 2009-11-27 EP EP09775302A patent/EP2370094A1/en not_active Withdrawn
- 2009-11-27 AU AU2009321249A patent/AU2009321249B2/en active Active
- 2009-11-27 SG SG2011037967A patent/SG171820A1/en unknown
- 2009-11-27 US US13/130,862 patent/US9259406B2/en active Active
- 2009-11-27 MY MYPI2011002367A patent/MY164577A/en unknown
- 2009-11-27 NZ NZ593027A patent/NZ593027A/xx unknown
- 2009-11-27 PE PE2011001107A patent/PE20120340A1/es active IP Right Grant
- 2009-11-27 MX MX2011005670A patent/MX342625B/es active IP Right Grant
- 2009-11-27 WO PCT/IB2009/055389 patent/WO2010061357A1/en not_active Ceased
- 2009-11-27 KR KR1020117014746A patent/KR101733252B1/ko active Active
- 2009-11-27 BR BRPI0921864-5A patent/BRPI0921864B1/pt active IP Right Grant
- 2009-11-27 EA EA201100864A patent/EA026867B1/ru not_active IP Right Cessation
- 2009-11-27 JP JP2011538092A patent/JP2012510461A/ja not_active Withdrawn
- 2009-11-27 CA CA2744990A patent/CA2744990C/en not_active Expired - Fee Related
- 2009-11-27 UA UAA201108006A patent/UA107069C2/uk unknown
-
2011
- 2011-05-11 TN TN2011000232A patent/TN2011000232A1/fr unknown
- 2011-05-19 EC EC2011011062A patent/ECSP11011062A/es unknown
- 2011-05-24 IL IL213116A patent/IL213116B/en active IP Right Grant
- 2011-05-26 CR CR20110280A patent/CR20110280A/es unknown
- 2011-05-27 CO CO11065644A patent/CO6440557A2/es unknown
- 2011-05-27 CL CL2011001254A patent/CL2011001254A1/es unknown
- 2011-05-27 SV SV2011003924A patent/SV2011003924A/es unknown
- 2011-05-27 NI NI201100105A patent/NI201100105A/es unknown
- 2011-05-27 HN HN2011001417A patent/HN2011001417A/es unknown
- 2011-05-27 ZA ZA2011/03925A patent/ZA201103925B/en unknown
- 2011-06-13 MA MA33937A patent/MA32896B1/fr unknown
-
2015
- 2015-05-27 JP JP2015107404A patent/JP6148696B2/ja active Active
-
2017
- 2017-03-01 JP JP2017037860A patent/JP2017141233A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012510461A5 (https=) | ||
| AR073425A1 (es) | Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente la cd38 y la citarabina | |
| AR123305A2 (es) | Proteínas de unión a antígeno | |
| AR074219A1 (es) | Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y melfalan | |
| JP2020500538A5 (https=) | ||
| AR086579A1 (es) | Proteinas de union a antigeno | |
| JP2016536314A5 (https=) | ||
| JP2009102444A5 (ja) | 二次性骨腫瘍の治療のための抗PDGFRα抗体 | |
| AR071891A1 (es) | Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano) | |
| JP2013544492A5 (https=) | ||
| JP2012136541A5 (https=) | ||
| JP2013502204A5 (https=) | ||
| PH12016500859A1 (en) | Anti-human respiratory syncytial virus (rsv) antibodies and methods of use | |
| RU2014143784A (ru) | Фармацевтическая композиция для лечения и/или предотвращения рака желчного пузыря | |
| AR074220A1 (es) | Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y vincristina y uso | |
| JP2017528476A5 (https=) | ||
| JP2012521217A5 (https=) | ||
| IN2012DN01328A (https=) | ||
| HRP20161740T1 (hr) | Ljudske molekule za vezanje koje su sposobne neutralizirati viruse influence a filogenetske skupine 1 i filogenetske skupine 2, te viruse influence b | |
| RU2014143785A (ru) | Фармацевтическая композиция для лечения и/или предотвращения рака печени | |
| JP2017528462A5 (https=) | ||
| JP2014076062A5 (https=) | ||
| JP2013520996A5 (https=) | ||
| NZ599405A (en) | Targeted binding agents against b7-h1 | |
| RU2012137498A (ru) | Фармацевтическая композиция для лечения и/или профилактики рака |